DUPILUMAB | B761055 | REGENERON PHARMACEUTICALS
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Mar. 28, 2029 | Active | Computed |
| 7-Year Orphan | Jan. 25, 1931 | Expired | Purple Book |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12398212(method of use) · relevance 95/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Top 50 of 201 AI-discovered patents by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Immunex Corporation v. Sanofi et al 1 patentdupilumab (anti-interleukin-4-receptor-alpha antibody) | C.D. Cal. | 2017-04-05 | Terminated 2021-08-02 | — |
| D. Mass. | 2017-03-20 | Terminated 2017-05-01 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.